Table 4.
Pathological characteristics of the low-grade ductal carcinoma in situ (DCIS) cases (156 cases) according to the presence or absence of associated invasive carcinoma (invasive breast carcinoma).
| Variable | Group 1 (pure DCIS) | Group 2 (DCIS+IBC) | p-value | OR (95% CI) | |
| n | 63 | 93 | |||
| Age (average) | 58.45 | 58.53 | - | ||
| ER/PR | Positive | 62 (98.4%) | 87 (93.5%) | 0.18 | 0.23 (0.02–1.99) |
| Negative | 1 (1.6%) | 6 (6.5%) | |||
| HER2 | Positive (3+) | 3 (4.8%) | 7 (7.5%) | 0.49 | 1.63 (0.40–6.5) |
| Negative (0/1+) | 60 (95.2%) | 86 (92.5%) | |||
| Molecular profile | Luminal (A+B) | 60 (95.2%) | 83 (89.2%) | 0.44 | – |
| Triple-positive | 2 (3.1%) | 4 (4.3%) | |||
| HER2 | 1(1.6%) | 3 (3.2%) | |||
| Triple-negative | 0 | 3 (3.2%) | |||
| CK 5/6 | Positive | 17/59 (28.8%) | 7/86 (8.1%) | 0.002 | 0.21 (0.08–0.57) |
| Negative | 42/59 (71.2%) | 79/86 (91.9%) | |||
| EGFR | Positive | 2/58 (3.4%) | 3/76 (3.9%) | 0.88 | 1.15 (0.18–7.12) |
| Negative | 56/58 (96.5%) | 73/76 (96%) |
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 2; CK 5/6: cytokeratin 5/6; EGFR: epidermal growth factor receptor (human epidermal growth factor 1).